- TSX-V:UVC
- OTCQB:FUVCF
Far-UVC, 216 nm
216 nm far-UVC, designed for occupied spaces.
Design target
US$350 module, 1 W target, against the best excimer fixture on the market.
US$200B+
US$200B+ annual disease burden addressable (Blueprint Biosecurity).
The Science
The electromagnetic spectrum spans from low-energy radio waves to high-energy gamma rays. Visible light sits in the middle, followed by higher-energy ultraviolet light. Shorter waves mean higher energy.
Vacuum UV
100 to 200 nm
Absorbed by air, cannot travel through normal atmosphere.
Far-UVC
200 to 230 nm
Wavelengths tuned to attenuate before penetrating human tissue, deadly for pathogens.
Conventional UVC
230 to 280 nm
Germicidal, but damages skin and eyes.
UVB & UVA
280 to 400 nm
Sunlight, tanning, vitamin D, but still hazardous to skin and eyes with prolonged exposure, and only weakly germicidal compared to UVC.
The “Sweet Spot”, 200 to 230 nm
01 · vs. Vacuum UV (<200 nm)
Wavelengths shorter than Far-UVC are absorbed by oxygen and nitrogen in the air before they can reach targets. They literally cannot travel through normal atmosphere.
02 · vs. Conventional UVC (>230 nm)
While effective for disinfection, conventional UVC (254 nm) penetrates human skin and eyes, causing damage. Use is strictly controlled and upper-room only.
Human Safety
Far-UVC photons attenuate in the outermost dead-cell layer of human tissue, a size effect: human cell membranes are far thicker than those of bacteria and virions, so the same photons reach pathogens but stop short of living cells.
Traditional germicidal UV (254 nm) is effective at killing pathogens but dangerous to human skin and eyes. This limits its use to unoccupied spaces or carefully controlled upper-room installations where the UV zone is above head height.
Far-UVC operates at shorter wavelengths (200 to 230 nm) that physically cannot penetrate the outer dead-cell layer of human skin (stratum corneum) or the tear layer of eyes. The photons are absorbed before they reach living cells.
Bacteria and viruses are different. They\u2019re small enough that the same Far-UVC photons can directly reach and destroy their DNA/RNA, no outer protective layer saves them.
254 nm vs 216 nm
254 nm
Conventional UVC
216 nm
SaniLux Far-UVC
Penetrates skin to living cells.
Stopped by the stratum corneum, dead skin cells.
Damages eyes and cornea.
Absorbed by the tear layer.
Strictly controlled, upper-room only.
Designed for occupied spaces: 216 nm far-UVC, below the 230 nm threshold.
Requires behavioral compliance.
Designed to meet exposure limits automatically, with no behavioural compliance.
Far-UVC Dual-Action Mechanism
01
Breaks nucleic-acid bonds. The primary germicidal mechanism shared with conventional UVC.
02
Disrupts viral and bacterial protein structure, a secondary mechanism unique to 200 to 230 nm Far-UVC, delivering additional kill efficacy beyond DNA damage alone.
The Breakthrough
SaniLux leverages proprietary nanoengineered materials to overcome the fundamental limitations of excimer lamps.
Design targets
10x
US$350 module, 1 W target, against the best excimer fixture on the market.
1W
Today’s filtered excimer modules deliver about 100 mW.
0 to 100%
Full power when the room is empty, exposure-limit output the moment people walk in.
No filter. No gas. No licence.
The spectrum is set by the material, not a plasma and a bandpass filter.
US$350
Commercial excimer fixtures sell for US$1,100 to 2,500.
Always on
Excimer fixtures meet occupied-space exposure limits by running about 7 percent of the day. SaniLux is designed to run continuously at the limit.
10,000 h
Design life at full output; longer at modulated output. Measured curves from the validation program.
Proprietary Nanoengineered Technology
Unlike competitors relying on excimer gas lamps, SaniLux uses novel solid-state materials engineered at the nanoscale.
216 nm Peak
Spectrum set by the emitter material; designed to need no optical filter.
Narrowly peaked
Clean emission profile, no harmful sidebands.
High Efficiency
More photons per watt of input power.
Scalable
Solid-state production designed for high-volume manufacturing.
Far-UVC output per dollar, mW per US$
1.4 at the 0.5 W validation gate, 2.9 at the 1 W design target.
10x far-UVC per dollar, target.
216 nm
Every photon calibrated to be blocked harmlessly by the protein-rich outer layer of human skin, and to destroy a virus the instant it hits one.
Industry Context
Until now, the industry has struggled to produce efficient Far-UVC light. Two approaches exist, both with fundamental problems.
Krypton-chloride gas discharge
Inefficient Output
Emit unwanted sideband peaks outside the Far-UVC region, presenting both danger to humans and generation of ozone. Expensive optical filters are required to attenuate and mitigate these problems.
Fixed Output
Fixed output, so fixtures meet exposure limits by switching off most of the day.
Low Efficiency
About 1 percent of wall power becomes far-UVC light.
Aluminum nitride semiconductor
Material Challenges
Requires aluminum nitride (AlN), a notoriously difficult semiconductor substrate to work with.
Not Yet Commercial
No 222 nm LED exists commercially; the shortest, at 233 to 235 nm, is above the safety threshold, and research devices below 230 nm run at 0.2 percent efficiency.
Uncertain Economics
No clear path to cost-effective manufacturing at scale. May never achieve commercial viability.
SaniLux: The Third Way
Proprietary nanoengineered materials engineered to deliver the promise of Far-UVC now, not in 10 to 15 years. Emitting at a peak of 216 nm, SaniLux is designed for a leap in both output and economic viability.
216 nm
Peak Emission
1 W
Far-UVC output target
10,000 h
Design life
In build
Validation units with Capgemini
Competitive Analysis
Core Technology
Excimer
KrCl gas + optical filter
SaniLux
Nanoengineered solid-state
Peak Wavelength
Excimer
222 nm (with sidebands)
SaniLux
216 nm (narrowly peaked)
Power Output
Excimer
About 100 mW
SaniLux
1 W design target
Output Control
Excimer
Fixed or coarse-step dimming
SaniLux
0 to 100 percent in nanoseconds
Unit Cost
Excimer
US$500 to 2,500
SaniLux
US$350 module (target)
Production at Scale
Excimer
High (complex filtering)
SaniLux
Low (solid-state)
Operation
Excimer
Intermittent dosing (about 7 percent duty cycle)
SaniLux
Continuous operation at the exposure limit
Maintenance
Excimer
High (bulb replacement)
SaniLux
Minimal (solid-state)
Form Factor
Excimer
Fixed, bulky
SaniLux
Flexible (bulb, panel, portable)
IP Dependency
Excimer
Most excimer products depend on Ushio’s exclusive Columbia licence
SaniLux
Own issued patent, no licence
Aviation Market
Excimer
Cannot serve (too slow/expensive)
SaniLux
Enables entire market
Transit Market
Excimer
Inadequate power density
SaniLux
Real-time disinfection
We own our technology. Our nanoengineered approach has zero licensing dependencies and enables market creation that excimer technology physically cannot achieve.
Market Creation
Excimer technology cannot serve these markets due to fundamental physics and economics limitations. Only SaniLux enables market creation at scale.
Category-Creating Opportunity
NEW
Market Creation
Current UVC solutions cannot work in occupied aircraft cabins. SaniLux is designed for continuous disinfection during flight.
Why Excimer Cannot Serve This Market
Fixed output, so fixtures meet exposure limits by switching off most of the day. Too expensive at fleet scale for pressurized cabins.
Global Transportation Network
65B+
Rides per Year
NEW
Market Creation
Buses, trains, subways serve billions of passengers annually. Impossible to protect with 254 nm UVC. SaniLux is designed for silent, continuous operation while passengers ride.
Why Excimer Cannot Serve This Market
Transit vehicles need continuous operation, and excimer fixtures meet exposure limits by switching off most of the day. Maintenance costs prohibitive at fleet scale.
Occupied Clinical Spaces
$3.2B+
Addressable Market
Far-UVC designed for continuous disinfection in occupied clinical spaces, including while surgeons operate.
The SaniLux Advantage
Designed for direct air and surface disinfection in the surgical field. No upper-room zone constraints.
Absenteeism Reduction = ROI
15,500+
Canadian Schools
Reduced sick days mean direct productivity ROI for employers and schools.
Why Scale Requires SaniLux Economics
At US$1,100 to 2,500 per excimer fixture, Far-UVC doesn’t pencil for schools or SMBs. At a US$350 module price target, Far-UVC becomes accessible to every classroom, office, and retail space.
Product Roadmap
Our nanoengineered technology enables flexible deployment across multiple form factors for different applications.
Q3 2027
Q1 2028
Q3 2028
Common across all form factors
Instant On
No warm-up time required.
Silent Operation
No fans or moving parts.
IoT Connected
Remote monitoring & control.
Low Maintenance
10,000 h design life.
Intellectual Property
SaniLux is built on a foundational Far-UVC patent that we now own and are actively expanding. Unlike most excimer products, which depend on Ushio\u2019s exclusive Columbia licence, we own our core technology outright with zero dependencies.
1
SaniLux patent (expanding), continuation and new applications in prosecution
Zero
License Dependencies
Owned
Core Technology
Novel
Nanoengineered
Competitive Moats
Novel nanoengineered materials not dependent on excimer gas or USHIO licensing.
Foundational Far-UVC patent owned outright, with an actively expanding patent family around it.
We own and develop the core Far-UVC technology in-house, with zero licensing exposure to third parties.
Only technology capable of serving aviation and transit markets at scale.
Third-Party Validation
Independent analysis of Far-UVC market opportunity and return on investment from the Blueprint Biosecurity Coalition.
Far-UVC represents one of the most promising technologies for pandemic preparedness and endemic disease reduction. The benefit-cost ratios documented across applications are exceptional.
Blueprint Biosecurity Coalition Report
30 to 290x
Benefit-cost ratio
1,000%
Annual ROI for aviation
Category
Creating Technology
Blueprint Biosecurity estimates
Strategic Validation
Chris Anderson
TED Curator
Rob Reid
After On Podcast
Blueprint Coalition
Biosecurity Think Tank
